title: [Comorbid states in Parkinson's disease: an effect of MAO-B inhibitors].
abstract: The comorbidity in Parkinson's disease (PD), which is closely related to the tolerability of antiparkinsonian drugs, is-'analyzed. The authors present the results of the studies that have confirmed the greater safety of rasagiline compared to dopamine receptor agonists in elderly patients. The effects of rasagiline, including combinations of this drug with antidepressants, on-depression in PD and the low risk,of the serotonin -syndrome caused by these combinations are considered. The studies demonstrated the effect of rasagiline on fatigue and cognitive functions in PD patients are described. Single cases of the development of impulsive compulsive disorders:in patients treated with- rasagiline are presented.
authors.affiliation: Pirogov Russian National Research Medical University, Moscow.
authors.forename: N V
authors.initials: NV
authors.lastname: Titova
authors.affiliation: Pirogov Russian National Research Medical University, Moscow.
authors.forename: E A
authors.initials: EA
authors.lastname: Katunina
authors.affiliation: Pirogov Russian National Research Medical University, Moscow.
authors.forename: N N
authors.initials: NN
authors.lastname: Sotnikova
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015897:Comorbidity; D003863:Depression / Q000139:chemically induced / Q000453:epidemiology; D005221:Fatigue / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D007189:Indans / Q000009:adverse effects* / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000453:epidemiology*
chemical_list: D000978:Antiparkinson Agents; D007189:Indans; D008996:Monoamine Oxidase Inhibitors; C031967:rasagiline